跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AG-IRBESARTAN HCTZ - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
AG-IRBESARTAN HCTZ
Authorized
STANDARD
AG-IRBESARTAN HCTZ
angita pharma inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
8996a2d552df97d2
Company
angita pharma inc.
Type
Standard
Approval Details
Approval Id
8996a2d552df97d2
Drug Approval Canada Name
AG-IRBESARTAN HCTZ
Product Name
AG-IRBESARTAN HCTZ
Status
Cancelled Post Market
Status Date
2022-09-21
Original Market Date
2018-09-06
Din
02476444
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
24:32.08
Atc Original
C09DA04 IRBESARTAN AND DIURETICS
Atc Name
c 09 da 04
Aig Number
0240086002
Company Name
angita pharma inc.
Company Address
1310 Rue Nobel, Boucherville, Quebec, Canada, J4B 5H3
Active Ingredients
HYDROCHLOROTHIAZIDE
12.5 MG
IRBESARTAN
300 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
8996a2d552df97d2
Type
Standard
Back to Health Canada Approvals